Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
Merck
Medtronic
Baxter

Last Updated: September 25, 2022

AVACLYR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Avaclyr patents expire, and when can generic versions of Avaclyr launch?

Avaclyr is a drug marketed by Fera Pharms Llc and is included in one NDA.

The generic ingredient in AVACLYR is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the acyclovir profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Avaclyr

A generic version of AVACLYR was approved as acyclovir by TEVA on April 22nd, 1997.

  Try it Free

Summary for AVACLYR
US Patents:0
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:AVACLYR at DailyMed
Drug patent expirations by year for AVACLYR

US Patents and Regulatory Information for AVACLYR

AVACLYR is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting AVACLYR

INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fera Pharms Llc AVACLYR acyclovir OINTMENT;OPHTHALMIC 202408-001 Mar 29, 2019 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Medtronic
Dow
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.